JP2021528449A5 - - Google Patents

Info

Publication number
JP2021528449A5
JP2021528449A5 JP2020571762A JP2020571762A JP2021528449A5 JP 2021528449 A5 JP2021528449 A5 JP 2021528449A5 JP 2020571762 A JP2020571762 A JP 2020571762A JP 2020571762 A JP2020571762 A JP 2020571762A JP 2021528449 A5 JP2021528449 A5 JP 2021528449A5
Authority
JP
Japan
Prior art keywords
compound according
spp
residue
compound
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020571762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528449A (ja
JP7488774B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/066819 external-priority patent/WO2020002325A1/en
Publication of JP2021528449A publication Critical patent/JP2021528449A/ja
Publication of JP2021528449A5 publication Critical patent/JP2021528449A5/ja
Priority to JP2024077064A priority Critical patent/JP2024109664A/ja
Application granted granted Critical
Publication of JP7488774B2 publication Critical patent/JP7488774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571762A 2018-06-25 2019-06-25 化合物 Active JP7488774B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024077064A JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25
US62/689,602 2018-06-25
PCT/EP2019/066819 WO2020002325A1 (en) 2018-06-25 2019-06-25 Compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024077064A Division JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Publications (3)

Publication Number Publication Date
JP2021528449A JP2021528449A (ja) 2021-10-21
JP2021528449A5 true JP2021528449A5 (enExample) 2022-07-07
JP7488774B2 JP7488774B2 (ja) 2024-05-22

Family

ID=67107423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571762A Active JP7488774B2 (ja) 2018-06-25 2019-06-25 化合物
JP2024077064A Ceased JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024077064A Ceased JP2024109664A (ja) 2018-06-25 2024-05-10 化合物

Country Status (31)

Country Link
US (3) US11459357B2 (enExample)
EP (2) EP3810633B1 (enExample)
JP (2) JP7488774B2 (enExample)
KR (1) KR20210054500A (enExample)
CN (2) CN118878638A (enExample)
AR (1) AR116663A1 (enExample)
AU (2) AU2019294261B2 (enExample)
BR (1) BR112020026663A2 (enExample)
CA (1) CA3103158A1 (enExample)
CO (1) CO2020016080A2 (enExample)
DK (1) DK3810633T3 (enExample)
EA (1) EA202092819A1 (enExample)
ES (1) ES2971732T3 (enExample)
FI (1) FI3810633T3 (enExample)
HR (1) HRP20240028T1 (enExample)
HU (1) HUE065134T2 (enExample)
IL (2) IL279620B2 (enExample)
LT (1) LT3810633T (enExample)
MA (1) MA52946B1 (enExample)
MD (1) MD3810633T2 (enExample)
MX (1) MX2020013811A (enExample)
PH (1) PH12020552240A1 (enExample)
PL (1) PL3810633T3 (enExample)
PT (1) PT3810633T (enExample)
RS (1) RS65128B1 (enExample)
SG (1) SG11202012747VA (enExample)
SI (1) SI3810633T1 (enExample)
TW (2) TWI851584B (enExample)
UA (1) UA128162C2 (enExample)
WO (1) WO2020002325A1 (enExample)
ZA (1) ZA202301937B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
DK3810633T3 (da) * 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
WO2022262823A1 (zh) * 2021-06-18 2022-12-22 华南理工大学 活性氧自由基响应的多粘菌素前药化合物及其应用
CN120574287B (zh) * 2025-06-10 2026-07-03 中国药科大学 一种抗菌肽、组合物及应用
CN121159640A (zh) * 2025-07-24 2025-12-19 中国药科大学 一种抗菌肽、药物组合物及应用
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (enExample) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
JP2007507512A (ja) 2003-09-30 2007-03-29 コーヒ コーポレーション 熱傷を治療するための組成物および方法
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
MX355217B (es) 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
KR20160135739A (ko) * 2014-03-11 2016-11-28 뉴 파마 라이센스 홀딩스 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
BR112017010888A2 (pt) * 2014-12-17 2018-02-27 Hoffmann La Roche método para produzir um produto de conjugação enzimática de três polipeptídeos
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
JP7367950B2 (ja) * 2015-09-29 2023-10-24 モナッシュ ユニバーシティ 抗菌性ポリミキシン誘導体化合物
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
DK3810633T3 (da) * 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
WO2020014501A1 (en) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Similar Documents

Publication Publication Date Title
JP2017510570A5 (enExample)
JP2017510580A5 (enExample)
HRP20240028T1 (hr) Spojevi
HRP20220387T1 (hr) Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima
RU2014143821A (ru) 1, 3, 4-ОКСАДИАЗОЛЬНЫЕ И 1, 3, 4-ТИАДИАЗОЛЬНЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗЫ
HRP20221217T1 (hr) Spojevi inhibitori beta-laktamaze
JP2015535847A5 (enExample)
JP2011513305A5 (enExample)
JP2009544602A5 (enExample)
JP2015527387A5 (enExample)
JPH0670068B2 (ja) セファロスポリン誘導体
JP2013542992A5 (enExample)
JP2016503778A5 (enExample)
JP2016528257A5 (enExample)
JP2015528468A5 (enExample)
JP2018500387A5 (enExample)
JP2016501864A5 (enExample)
JP2018521056A5 (enExample)
JP2019501123A5 (enExample)
JP2018523675A5 (enExample)
IN2012DN00611A (enExample)
CN106660962A (zh) 用作选择性抗菌剂的含2‑吡啶酮部分的芳基酰肼
JPS62294615A (ja) 抗菌剤
JP2019529469A5 (enExample)
JP2017530947A5 (enExample)